文献速递乳腺癌放疗

TIGIT阻断增强PD-1阻断联合放疗在三阴性乳腺癌模型中的疗效

TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model.
PubMed 文献 · Radiother Oncol · 2025-05-11

该研究分析公共转录组数据发现TIGIT主要表达于乳腺癌T细胞且与TNBC不良预后相关,并在小鼠TNBC模型中评估αPD-1、局部RT和αTIGIT的效果。结果显示αPD-1联合RT增加TIGIT+CD226+CD8+肿瘤浸润淋巴细胞,三联疗法产生协同抗肿瘤效应,增加照射及未照射肿瘤中CD8+肿瘤浸润淋巴细胞浸润、减少耗竭表型并降低Treg。

要点

  • TIGIT主要表达于乳腺癌T细胞,其表达与TNBC患者不良预后相关
  • αPD-1联合RT增加TIGIT+CD226+CD8+肿瘤浸润淋巴细胞,为αTIGIT疗效关键
  • 三联疗法协同增效,增加CD8+肿瘤浸润淋巴细胞浸润并减少Treg

核心结论

  • αTIGIT与αPD-1/RT联用通过增加CD8+肿瘤浸润淋巴细胞的浸润和活化并减少Treg而发挥协同效应。
  • 研究提示αTIGIT可能是增强αPD-1和RT在TNBC中抗肿瘤疗效的有效策略。

研究设计与样本

  • 分析公共转录组数据以识别TIGIT在乳腺癌T细胞上的表达模式及其预后影响。
  • 利用小鼠TNBC模型评估αPD-1、局部RT和αTIGIT的效果。
  • 分析肿瘤、肿瘤引流淋巴结和脾脏中的T细胞以评估治疗后的抗肿瘤免疫应答。

主要发现

  • TIGIT主要表达于乳腺癌T细胞,其表达与TNBC患者不良预后相关。
  • 小鼠模型中αPD-1联合RT增加TIGIT+CD226+CD8+肿瘤浸润淋巴细胞。
  • 与αPD-1/RT相比,三联疗法增加照射和未照射肿瘤中CD8+肿瘤浸润淋巴细胞浸润。
  • 三联疗法使CD8+肿瘤浸润淋巴细胞耗竭表型减少并增加脾脏CD8+ T细胞增殖。
  • αTIGIT联合αPD-1/RT显著减少肿瘤、肿瘤引流淋巴结和脾脏中的Treg。

临床怎么用

  • 在TNBC模型中,αPD-1联合RT基础上加用αTIGIT可协同增强抗肿瘤免疫应答。
  • αTIGIT与αPD-1/RT联用可增加CD8+肿瘤浸润淋巴细胞浸润和活化并减少Treg。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: T-cell immunoreceptor with Ig and ITIM domains (TIGIT) suppresses functions of CD8+ T cells, and radiation therapy (RT) induces stimulation of regulatory T cells (Tregs), thereby limiting antitumor efficacy. This study aims to investigate the role of TIGIT in the immunosuppressive tumor environment and evaluate the potential of TIGIT blockade (αTIGIT) to enhance antitumor immune responses. METHODS: We analyzed public transcriptomic data to identify the expression patterns of TIGIT on T cells in breast cancer and its prognostic impact. In addition, a murine TNBC model was utilized to evaluate the effects of αPD-1, local RT, and αTIGIT. T cells in tumors, tumor-draining lymph nodes (TdLNs), and the spleen were analyzed to assess the antitumor immune responses upon the treatments. RESULTS: The analysis revealed that TIGIT is predominantly expressed on T cells within breast cancer, and the expression of TIGIT was associated with poor outcomes in TNBC patients. In the murine model, the combination of αPD-1 and RT increased TIGIT+CD226+CD8+ TILs, which are crucial for the efficacy of αTIGIT. Adding αTIGIT to αPD-1 and RT (αPD-1/RT) resulted in a synergistic antitumor effect, which was accompanied by increased infiltration of CD8+ TILs in both irradiated and nonirradiated tumors by the triple combination therapy compared to αPD-1/RT. The triple combination therapy also resulted in a less exhausted phenotype among CD8+ TILs and increased the proliferation of splenic CD8+ T cells. Moreover, αTIGIT significantly reduced Tregs in tumors, TdLNs, and the spleen when combined with αPD-1/RT. CONCLUSION: αTIGIT exhibits synergistic effects when added to αPD-1/RT by increasing the infiltration and activation of CD8+ TILs while reducing Tregs. The study suggests that αTIGIT could be an effective strategy to enhance the antitumor efficacy of αPD-1 and RT in TNBC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kim S, Jeon SH, Kim Y, et al. TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model. Radiother Oncol. 2025. PMID: 40360046. doi:10.1016/j.radonc.2025.110932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。